Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome
New Drug Application (NDA) enabling Phase 2b Protocol submission to the U.S. FDA Targets Rare Disease Population with Significant Unmet Need and Lifetime Burden of Repeated Skin Cancer Surgeries New Drug Application (NDA) enabling Phase 2b Protocol submission to the U.S. FDA Targets Rare Disease Population with Significant Unmet Need and Lifetime Burden of Repeated Skin Cancer Surgeries
New Drug Application (NDA) enabling Phase 2b Protocol submission to the U.S. FDA Targets Rare Disease Population with Significant Unmet Need and Lifetime Burden of Repeated Skin Cancer Surgeries New Drug Application (NDA) enabling Phase 2b Protocol submission to the U.S. FDA Targets Rare Disease Population with Significant Unmet Need and Lifetime Burden of Repeated Skin Cancer Surgeries
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.